BioCentury
ARTICLE | Clinical News

Tivantinib: Completed Phase III enrollment

May 28, 2012 7:00 AM UTC

ArQule and Daiichi Sankyo completed enrollment in the double-blind, international Phase III MARQUEE trial comparing twice-daily 360 mg oral tivantinib plus daily 150 mg oral Tarceva erlotinib vs. placebo plus Tarceva in about 1,000 patients with locally advanced or metastatic NSCLC who received 1-2 prior systemic anti-cancer therapies. The company has an SPA from FDA for the trial. ArQule is co-developing tivantinib with Daiichi Sankyo on a worldwide basis outside of certain Asian countries, where ArQule licensed rights to Kyowa in 2007 (see BioCentury, Nov. 5, 2007 & Nov. 17, 2008). ...